Le Lézard
Classified in: Health, Science and technology
Subject: PER

Digital Infuzion Welcomes Dr. Davyd Chung as Chief Growth Officer to Spearhead Strategic Expansion


Digital Infuzion, a leader in health information technology solutions, is thrilled to announce the appointment of Dr. Davyd Chung as its new Chief Growth Officer. Digital Infuzion is confident that Dr. Chung's strategic insights and leadership will propel the company towards new horizons of success and innovation in the health IT sector.

ROCKVILLE, Md., May 6, 2024 /PRNewswire-PRWeb/ -- Joining the team on April 8, Dr. Davyd Chung brings over two decades of distinguished expertise in strategic growth and business development within the health sector.

"Davyd's background in biomedical research and his proven track record in strategic growth are tremendous assets to us," said Hemant Virkar, CEO of Digital Infuzion. "We are excited to collaborate with him to extend our impact on healthcare and enable our clients to achieve exceptional outcomes."

As the former Vice President of Strategy and Growth at DLH Corp., Dr. Chung played a pivotal role in expanding the company's footprint across the Federal Health market, including agencies such as Health and Human Services (HHS) and Defense Health Agency (DHA). He managed a comprehensive $2 billion business development pipeline, significantly enhancing company capabilities in capture and proposal processes.

Prior to his tenure at DLH, Dr. Chung served as the Executive Director of Research and Strategic Operations at the University of Illinois-Chicago (UIC) Cancer Center, where he orchestrated strategic initiatives to increase federal and commercial funding, operational efficiency, and pharmaceutical partnerships, thereby advancing clinical and research integrations.

Dr. Chung's extensive background also includes impactful positions at the National Institutes of Health (NIH), where his roles at the National Cancer Institute (NCI) and the National Institute of Child Health and Human Development (NICHD) solidified his reputation as a leader in public health and biomedical research.

Dr. Chung expressed his enthusiasm about his new role, noting, "I am honored to join Digital Infuzion and contribute to its noble mission of advancing healthcare through innovative technology. I look forward to leveraging my experience to enhance our offerings and help our clients navigate the complexities of healthcare modernization."

Holding a PhD in Physiological Molecular Biology from the University of Illinois at Urbana-Champaign, Dr. Chung's deep-rooted knowledge in biomedical research perfectly aligns with Digital Infuzion's mission to enhance health-focused organizations' capacities to improve lives.

About Digital Infuzion: Digital Infuzion is a provider of customized IT solutions that empower health-focused organizations to achieve more efficient, impactful, and cost-effective outcomes. Located in Rockville, Maryland, the company is dedicated to improving lives through the integration of innovative technology solutions in healthcare.

Media Contact

Eileen Moore, Chief of Staff to the CEO, Digital Infuzion, LLC, 1 301.948.4871, [email protected], www.digitalinfuzion.com

LinkedIn

SOURCE Digital Infuzion, LLC


These press releases may also interest you

at 02:05
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...

at 01:30
Urinary Catheters Market size is set to grow by USD 2.44 bn from 2024-2028, rising geriatric population with urinary incontinence to boost the market growth, Technavio
The global urinary catheters market  size is estimated to grow by USD 2.44 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 7.63%  during the forecast period. ...

at 00:25
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

19 mai 2024
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

19 mai 2024
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP agilon health, inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm (AGL)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

More news about Health...


News published on and distributed by: